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Significance 
By investigating cell surface proteins of Ewing sarcoma we have identified an antigen 
that is uniquely expressed on these tumour cells compared with mesenchymal stem 
cells. This protein acts as a target for antibody drug conjugates that are internalized 
and can kill these tumour cells, presaging translating to clinical use in treating Ewing 
sarcoma, especially metastatic disease. 
 
Abstract 
The cell surface proteome of tumours mediates the interface between the 
transformed cells and the general micro-environment including interactions with 
stromal cells in the tumour niche and immune cells such as T cells. In addition, the 
cell surface proteome of individual cancers defines biomarkers for that tumour type 
and potential proteins that can be the target of antibody-mediated therapy. We have 
used next generation deep RNA sequencing (RNA-seq) coupled to an in-house 
database of genes encoding cell surface proteins (herein referred to as the 
surfaceome) as a tool to define a cell surface proteome of Ewing sarcoma compared 
with progenitor mesenchymal stem cells. This subtractive RNA-seq analysis revealed 
a specific surfaceome of Ewing and showed unexpectedly that the leucine-rich 
repeat and immunoglobulin domain protein LINGO1 is expressed on over 90% of 
Ewing sarcoma tumours, but not expressed in any other somatic tissue apart from 
the brain. We found that the LINGO1 protein acts as a gateway protein internalizing 
into the tumour cells when engaged by antibody and can carry antibody conjugated 
with drugs to kill Ewing sarcoma cells. Therefore, LINGO1 is a novel, unique and 
specific biomarker and drug target for the treatment of Ewing sarcoma.  
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Targeted cancer treatment options rely on the identification of specific target proteins 
that allow the differentiation between normal and malignant cells. Monoclonal 
antibodies that selectively bind to such target proteins have been successfully 
utilized in the clinic. Cell surface proteins are excellent targets for antibody-based 
therapeutics due to their accessibility. Mechanisms by which antibodies can induce 
tumour cell killing include Antibody-Dependent Cell mediated Cytotoxicity (ADCC) 
and specific delivery of a cytotoxic payload to tumour cells using antibody-drug 
conjugates (ADC) (1). However, there are few cancer-specific cell surface proteins 
that can be invoked for antibody targeting. Of the predicted number of about 21,000 
human genes, approximately 4700 are predicted to be membrane associated. 
Methods are required to filter this information and allow further prediction of cell 
surface molecules. The analysis of whole cellular transcriptomes by next generation 
deep RNA sequencing (RNA-seq) is a new method for target discovery, which can 
be utilized as a surrogate tool for the analysis of the proteome including the entirety 
of cell surface proteins, called the surfaceome (2, 3).  
The Ewing sarcoma family of tumours (ESFT) are aggressive bone and soft tissue 
tumours with a high propensity to metastasise. Ewing sarcoma is the second most 
common bone tumour of children and adolescents with the mean age of diagnosis 
being 15 years of age.(4, 5). The current standard of care treatment is multimodal 
treatment including systemic chemotherapy with either radiation or surgery often with 
limb amputation in patients with local recurrence (6, 7). However, despite aggressive 
treatment the 5-year survival rate is 60-70% for localized disease and drops sharply 
to only 30% when the cancer metastasises (4, 8). There is therefore a need for novel 
targeted therapies for these cancers, that will overcome the limitations of the current 
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treatment regimens, namely the severe side effects and very limited effectiveness for 
metastasized disease.  
Ewing sarcoma arises as a consequence of balanced chromosomal translocations 
leading to an in frame fusion of the EWSR1 gene with a member of the ETS family of 
genes, principally resulting fusion protein is EWS-FLI1, which acts as an aberrant 
transcription factor and induces global changes in gene expression that are essential 
for malignant transformation and tumour formation (4). The most likely cells of origin 
of Ewing sarcoma are mesenchymal stem cells (MSCs) since these cells are 
permissive for EWS-FLI1, which is toxic for many cell lines (9, 10). In addition, EWS-
FLI1 expression in MSCs induces a gene expression profile that is highly similar to 
EWS (11) while EWS-FLI1 silencing in ES cell lines leads to the conversion towards 
a MSC expression profile (12).  
To facilitate the development of a general approach to identify candidate cell surface 
proteins, we examined the Ewing sarcoma cell surface using a new RNA-seq 
surfaceome database to analyze whole transcriptomes of polyA+ RNA from three cell 
lines with two MSC lines (subtractive RNA-seq). Our work on the Ewing sarcoma 
RNA-seq is a proof-of-concept and revealed a set of candidate target proteins that 
are differentially expressed in the tumour cells. One of these target genes is the 
leucine-rich repeat and Ig domain containing protein 1 (LINGO1) first identified as a 
component of protein complex on brain cells (13). Our data suggest that LINGO1 is a 
highly specific drug target and novel biomarker of Ewing sarcoma tumours. 
 
Ewing sarcoma surfaceome & LINGO1 
-  5  - 
Results 
Generation of a database of genes encoding surfaceome proteins 
The use of data for genes encoding cell surface proteins (the surfaceome) (3), has 
increasing importance since whole transcriptome data can now be obtained by next 
generation deep sequencing of populations of cells and single cells (14-16). Further, 
complete genome sequencing have defined all the coding genes allowing 
classification of gene products into functional categories and into sub-cellular 
locations, such as nucleus, mitochondria, membrane-association, cell surface and 
secreted. We have developed surfaceome database based on the sources and 
criteria listed in SI Appendix, Table S1A. The potential surfaceome genes were 
classified as gold, silver or bronze (SI Appendix, Table S1B). These surfaceome 
database class designations were established to give degrees of confidence about 
the validity of each candidate surface protein encoding mRNA (for instance gold is 
where a protein has been shown to have surface expression) whereas the two other 
classes distinguish higher and lower confidence is such predictions. Accordingly, 
next generation deep RNA-seq data can be filtered using the surfaceome database 
to list genes that will encode proteins at the cell surface and, by comparing two 
related cell populations, candidate proteins can be identified that are differently 
expressed (subtractive RNA-seq).  
 
Analysis of RNA-seq surfaceome data reveals Ewing sarcoma cell surface 
proteins 
Possible novel surface proteins that could be therapeutic targets for Ewing sarcoma 
were investigated by implementing the filtering of whole transcriptome deep 
sequencing of RNA from three Ewing sarcoma cell lines (A673, TC-32 and TTC-466) 
compared with two MSC lines (5H and 4+v) (17). The complete data sets for the five 
RNA populations are given in Dataset S1. We compared the two whole 
transcriptomes with surfaceome encoding transcripts (Figure 1 and SI Appendix, 
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Figure S2) as well as transcription factors, cell cycle and cell signaling proteins (SI 
Appendix, Figures S1 and S2).  The subtracted surfaceome RNA-seq data set is 
listed in Dataset S2. This revealed 839 mRNA transcripts that are preferentially 
expressed in EWS and 931 transcripts that are preferentially expressed in the MSC 
lines (Figure 1A). By filtering the RNA-seq data with our surfaceome database and 
subtracted between the two RNA-seq data sets, we found that 196 mRNAs are 
differentially expressed in Ewing sarcoma, with limited expression in MSCs, while 
317 genes were up-regulated in the MSC lines (Figure 1B). This includes known 
Ewing sarcoma associated proteins such as CD99 (Dataset S2) but CD99 is known 
as a Ewing sarcoma marker and further CD99 mRNA expression did not fulfill the 
selectivity criteria used in our study. 
The most highly differentially expressed candidate mRNAs in Ewing sarcoma were 
selected using more stringent criteria, i.e. high expression levels in all three EWS cell 
lines and no (or very low) expression in both MSC lines, excluding genes with high 
variability in their expression levels between the Ewing cell lines. This derived a set 
of ten genes in Ewing sarcoma and four genes in the MSC that fit these criteria (SI 
Appendix, Table S2); these mRNAs are also indicated in Figure 1B. The attribution of 
the expression of the 14 genes was confirmed using by real time PCR (qRT-PCR) 
using cDNA made from the three Ewing cell lines and the two MSC lines. All ten 
candidate target genes expressed in the Ewing cell lines could not be detected in the 
MSC lines, while the four MSC-specific cells were detected in the MSC lines, but not 
in the Ewing cell lines (Figure 2).  
 
LINGO1 is a novel biomarker for Ewing sarcoma tumours 
One of the mRNAs observed in the Ewing RNA-seq group encodes the leucine 
repeat and Ig domain containing protein LINGO1. The protein is expressed in 
neuronal tissue and is naturally part of the Nogo receptor (13, 18). A most striking 
characteristic of LINGO1 is its large and well-characterized extracellular domain (19). 
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This made LINGO1 stand out as a potential new biomarker and drug target in Ewing 
sarcoma. The expression of LINGO1 mRNA was studied in a larger panel of Ewing 
sarcoma cell lines, all of which carry the characteristic chromosomal translocations 
causing EWS- fusion genes. qRT-PCR analysis of eight Ewing sarcoma cell lines 
and three MSC lines shows that LINGO1 mRNA could be detected in all of the EWS 
lines, whereas LINGO1 was not detected in the MSC lines (Figure 3A).  
The analysis of the surfaceome by mRNA expression is a surrogate for the actual 
proteome and we therefore determined LINGO1 protein levels in the same panel of 
cell lines using Western blot analysis. The upper panels in Figure 3B shows LINGO1 
protein is detected in all of the Ewing cell lines, but not in the MSCs. We verified the 
presence of the EWS-FLI1 fusion protein by Western blotting with anti-FLI1 antibody 
(Figure 3B, right) or by Western blotting with anti-EWS in the three Ewing cell lines 
expressing the alternative fusion proteins EWS-ERG (TTC466 and RM82) or EWS-
FEV (STAET10) (Figure 3B, left). In this analysis, the upper band represents cellular 
EWS protein, while the bottom band represents the fusion protein.  
LINGO1 is expressed in all the Ewing sarcoma cell lines tested. The spectrum of 
primary Ewing sarcoma patient expression was analyzed using tissue microarrays of 
paraffin-embedded cores taken from tumour biopsies. CD99 is a known immune-
histochemical marker of EWS and served as a positive control. LINGO1 expression 
levels were quantified according to staining intensities. Fifty six patient samples were 
analyzed in total and we detected LINGO1 expression in 91% of these samples. 
Twelve samples showed weak, twenty five samples moderate and fourteen samples 
strong LINGO1 expression levels (SI Appendix, Table S3). Figure 3C shows 
examples of weak, moderate and strong staining intensities (designated patient 1, 2 
and 3 respectively) in different Ewing sarcoma patient samples, all of which are 
clearly positive for CD99 expression. Paraffin-embedded MSCs from our cultured 
lines served as negative controls in this experiment and show only background 
staining (Figure 3C). LINGO1 RNA expressing was compared in the A673 Ewing cell 
Ewing sarcoma surfaceome & LINGO1 
-  8  - 
line with RNA from a rhabdomyosarcoma cell line and two neuroblastoma lines by q-
RT-PCR (SI Appendix, Figure S3). We used the previously identified Ewing sarcoma 
marker ITM2A (20) (11) and KCNN1 that we have found in our study (SI Appendix, 
Table S2). LINGO1 and ITM2A expression parallel each other and only show 
expression A673 and not in the rhabdomyosarcoma or neuroblastomas. KCNN1 on 
the other hand is relatively highly expressed in the neuroblastoma lines and thus 
clearly not only in Ewing sarcomas. A micro-array analysis studying expression in 
several Ewing sarcoma cell lines and other sarcoma types (including RMS) shows 
LINGO1 is consistently and significantly up-regulated only in Ewing sarcoma (21).  
The normal expression of LINGO1 has been reported to be restricted to some 
neuronal cells and precursors beyond the blood brain barrier (BBB) (13, 22). Further, 
there are human RNA data showing negligible expression outside the CNS 
http://www.proteinatlas.org/ENSG00000169783-LINGO1/tissue . We confirmed that 
in mouse tissues, using RT-PCR, we only observed a LINGO1 product from brain 
tissue and not from a range of somatic tissues (SI Appendix, Figure S4). The 
unexpected expression of LINGO1 in Ewing sarcoma suggests that there may be a 
relationship to the EWS gene fusion that comes from the consistent chromosomal 
translocation in these tumours. Stable MSC lines were established in which EWS-
FLI1 and eGFP expression are driven by a bidirectional doxycycline inducible 
promoter. Stable clones were induced with 1µg/ml doxycycline and 5 clones 
displaying high eGFP induction levels were selected. Western analysis with anti-FLI1 
antibody to detect the EWS-FLI1 fusion protein and quantitative RT-PCR of EWS-
FLI1 mRNA revealed high induction levels of EWS-FLI1 in the selected clones. (SI 
Appendix, Figure S5A, B). All five inducible MSC clones showed stimulation of 
LINGO1 expression, to a greater or lesser extent compared to the induction of 
NR0B1 (the gene encoding DAX1 that is a direct target of EWS-FLI1 (23) expression 
(SI Appendix, Figure S5C, D). These data endorse LINGO1 as part of the EWS-FLI1 
transcriptome landscape.  
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LINGO1 is expressed on the surface of Ewing sarcoma cell lines and 
internalizes when bound by IgG 
The immuno-histochemistry of the Ewing sarcoma tumours show surface staining 
with anti-LINGO1 monoclonal antibody (Figure 3C). Surface expressed LINGO1 
protein was confirmed using flow cytometry with eight different Ewing sarcoma cell 
lines compared to the three MSC lines (Figure 4). All eight Ewing sarcoma cell lines 
have LINGO1 on their cell surface. These data demonstrate that LINGO1 is a 
differentially expressed cell surface protein in Ewing sarcoma making it a potentially 
useful target for antibody-based therapies, such as delivery of Antibody Drug 
Conjugates (ADC). In order to achieve cell toxicity by ADC methods, the reagent has 
to bind to a cell surface target and consequently become internalized to deliver the 
drug. LINGO1 internalization was examined by co-staining the Ewing cell line A673 
with FITC-coupled anti-LINGO1 antibody and antibodies recognizing either the early 
endosome (EEA1) or the lysosome (LAMP1) proteins. Following incubation either at 
4°C or at 37°C for 1.5 hours, cells were fixed, permeabilized, and incubated with 
Alexa Fluor 594 coupled anti-rabbit secondary antibodies, and analyzed by confocal 
microscopy.  We found the anti-LINGO1 antibody was mainly localized at the plasma 
membrane of cells incubated at 4°C (Figure 5A and B, top) while the antibodies 
binding EEA1 or LAMP1 were internal to the cells After 1.5 hours incubation at 37°C, 
the majority of anti-LINGO1 antibody has been internalized and can be seen in the 
cytoplasm of the cells (Figure 5A and B, bottom). This has been visualized by time-
lapse video shown in the SI Appendix, Video 1. A673 cells were incubated (37°C in 
DMEM medium with 10% FBS) with anti-LINGO1 Alexa Fluor® 488 and green 
fluorescence time-lapse images overlaid with labelled acidic organelles (lysosomes) 
using LysoTracker® Deep Red (red). Cells were incubated at and images were 
collected at 25 seconds intervals for 1 hour using a DeltaVision Elite Imaging 
System. After internalization, the anti-LINGO1 partially co-localized with the early 
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endosomal and the lysosomal markers suggesting that LINGO1 protein is 
internalized via the endosome-lysosome pathway, following binding with the anti-
LINGO1 bivalent IgG antibody. As a negative controls, MSCV4 and HEK293 cells 
(non-expressers of LINGO1 antigen) were incubated with or without anti-LINGO1 
Alexa Fluor® 488 (SI Appendix, Videos 2, 3, 4). 
 
LINGO1 can be used as target for Ewing sarcoma cell killing  
The unique cell surface expression of LINGO1 protein in Ewing sarcoma compared 
to other somatic tissues and the phenomenon of antibody-mediated internalization 
suggests that the protein can serve as a mediator of cell killing using antibody drug 
conjugates (ADC). This was analyzed using doxorubicin in ADC assays with the 
A673 Ewing line since these cells are known to be doxorubicin-sensitive (24). A dose 
response analysis confirmed doxorubicin-sensitivity at about 50uM (Figure 6A). The 
effect of anti-LINGO1 ADC was assayed in A673 (Figure 6B) by coupling doxorubicin 
to anti-LINGO1 antibody Li81 and incubating either A673 cells or the MSC line 5Blast 
for up to 72 hours. A673 cells were also incubated with Li81 antibody alone without 
conjugated doxorubicin. Cell death was evident in the A673 cells incubated with the 
anti-LINGO1 ADC at 48 hours resulting in about 25% toxicity within the culture at 72 
hours (Figure 6B). The ADC did not affect the percentage viability of the MSC cells, 
that lack LINGO1 expression, nor did the antibody alone affect the A673 viability.  
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Discussion 
The cancer cell surfaceome 
The use of antibody therapies in human diseases, in particular cancer, is gaining 
importance but a major technical challenge is finding the few cell surface proteins 
that provide distinguishing marks for specific cancer types. In addition, with the 
advent of new technologies for tumour targeting, such as invoking T cell responses 
with chimaeric antigen receptors (25), the requirement for specific tumour cell 
surface markers has become a critical component for implementing these methods. 
There are various possible approaches to determining the cell surface proteomes of 
a tumour types but an under-exploited approach is to utilize the genome sequence 
and associated annotation resources that provides both the full gamut of human 
genes, their likely splice variants and their protein products. By analyzing these 
sequence data, it is possible to classify gene products in terms of likely function but 
critically also subcellular location, in particular whether the proteins are likely to be at 
the cell surface. 
We have utilized the human genome sequence data and motifs to assort the genes 
into those encoding proteins that are known to be, or have a likelihood based on the 
presence of a membrane motif, cell surface proteins (the surfaceome database). This 
builds on previously published analysis (3) and now includes more comprehensive 
sets of proteins (all annotated gene products) and respective annotations (including 
both Uniprot annotations and amino-acid sequence feature predictions). We have 
assorted the proteins according to likelihood of cell surface expression as gold 
(known cell surface such as CD markers), silver (multiple independent feature 
predictions or annotations) and bronze (single feature prediction or annotation). This 
surfaceome database resource can be used to interrogate next generation deep 
RNA-seq data from a particular cell type to produce a cell-associated surfaceome. 
These data can be cell-type specific if suitable control RNA-seq data are available to 
allow subtraction of expression profiles (subtractive RNA-seq). This approach is 
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applicable to human disease studies such as cancer biology and auto-immunity but 
also to developmental biology where cell surface changes influence cell fate (26).  
 
LINGO1 is a potential therapy target in Ewing sarcoma 
We have applied this approach to assess surfaceome targets in Ewing sarcoma 
which is an aggressive bone and soft-tissue sarcoma in adolescents and young 
adults. Current treatments involve intensive chemotherapy, radiotherapy and radical 
surgery. In an attempt to invoke molecular biology methods to identify new 
approaches to Ewing sarcoma therapy, we have generated RNA-seq data from 
tumour cells and compared these with data from mesenchymal stem cell lines to 
carry out subtractive RNA-seq. Among our list of differentially expressed candidate 
surfaceome targets were members of immunoglobulin-like domains, the G protein-
coupled receptor superfamily, ion channels as well as ion transporters (SI Appendix, 
Table S2) and includes seven proteins, that have not previously been highlighted as 
EWS surface targets (LINGO1; KCNN1, CDH23, ADRA1D, SLC24A3, CACNA1H, 
SLC29A4). A recent review has summarized available Ewing sarcoma transcriptome 
data (27). We have used our surfaceome database mining strategy to assess the 
published RNA-seq datasets (28, 29) (this excludes one dataset that is currently not 
publically available due to patient confidentiality (30)) and we found excellent 
concordance with the expression values found for our Ewing sarcoma surfaceome 
candidates shown in SI Appendix, Table S2. In both datasets, the expression level of 
the Ewing’s up-regulated candidates positively correlates with the expression level of 
the translocation fusion EWS-FLI1, and conversely mRNAs up-regulated in MSC 
negatively correlates with EWS-FLI1. Amongst these outstanding proteins is LINGO1 
that consists of 620 amino acids with a large extracellular domain, the structure of 
which has been elucidated by crystallography (19), and which is displayed at the cell 
surface, thereby favouring immune regulation approaches mediated by antibody 
binding.  
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  LINGO1 is a prominent molecule since an extracellular immunoglobulin 
domain and a leucine repeat domain have provided antigenic epitopes for antibody 
derivation, including an anti-LINGO1 antibody that is currently in clinical trials (31). 
LINGO1 is a component of the Nogo receptor signaling complex and plays a role in 
regulation of neuronal survival, axon regeneration, oligodendrocyte differentiation 
and myelination (13, 18). LINGO1 is exclusively expressed in the CNS (32) as we 
have verified with RT-PCR analysis of RNA from various mouse tissues (SI 
Appendix, figure S4). Brain-expressed LINGO-1 is largely protected from circulating 
antibodies by the blood brain barrier. The restricted expression pattern and 
accessible extracellular domain make LINGO1 a attractive target for antibody-based 
therapies.  
  Our results show that an antibody binding to the extracellular domain of 
LINGO1 can induce cell killing when the anti-LINGO1 antibody carries a cytotoxic 
drug as an ADC. These immunological properties are presumably due to the efficient 
internalization of the cell surface LINGO1 protein on binding to the bivalent IgG1 
antibody used. Thus ADC is a most promising method for treatment of Ewing 
sarcoma. In Ewing, the site and size of the primary tumour are prognostic factors for 
outcome but the most important factor is the presence of metastatic disease at 
presentation which is an adverse factor. About a quarter of patients present with 
disseminated disease and the front line therapy (surgery and chemotherapy) results 
in low 5 year survival. Recurrent disease is associated with a very poor prognosis 
and new therapeutic approaches are required (33). The use of targeting strategies to 
LINGO1 is a novel potential approach to improve this outcome.  
  The expression of LINGO1 on brain cells is an issue with the use of 
antibodies carrying toxic drugs. The blood-brain barrier is an effective gross 
prevention of blood supply because of the tight junctions of the vessel endothelium 
but some macromolecule movement is possible. Thus ADC with anti-LINGO1 would 
need to be tested to assess this possible problem. Anti-LINGO1 bi-specific 
Ewing sarcoma surfaceome & LINGO1 
-  14  - 
antibodies could be an important approach to avoid toxicity issues. Special 
formulations of immuno-nanoparticles with drug payloads are developmental options 
that can also potentially overcome any toxicity issues. 
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Materials and Methods 
RNA-seq library preparation and data acquisition 
For RNA-seq analysis of the MSC lines 5H and 4+v and the EWS cell lines, A673, 
TC-32 and TTC-466, total RNA was extracted and sequencing libraries prepared 
before single end deep sequencing using an Illumina GA IIx to obtain 80bp reads.  
RNA-seq data and surfaceome database analysis was carried out as described in 
the Supporting Appendix.  Other general methods and associated references are 
available online in the the Supporting Appendix. 
Further supporting information and data files are available online. 
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Figure legends 
Figure 1. Gene expression quantification by RNA-seq reveals differentially 
expressed genes in Ewing sarcoma 
Mean expression values in the MSC lines are shown on the x axis and in the Ewing 
sarcoma cell lines on the y axis. Values are transcripts per million (TPM). Plots are 
shown for the entire transcriptome (A) or mRNA transcripts encoding surfaceome 
proteins (B). Each dot represents an mRNA transcript. Transcripts found to be 
significantly up-regulated in Ewing sarcoma or MSC are shown with red or blue dots 
respectively (for each transcript we carry out a modified t-test using the three EWS 
values and the two MSC values. From this test we obtain a p-value, corrected for 
multiple testing. A transcript is marked as up-regulated or down-regulated only if the 
corrected p-value is smaller than 0.05). The numbers, in panel B, indicate the 
surfaceome candidate target genes identified in Ewing sarcoma (1 -10) and MSC-
specific genes (11-14) (see SI Appendix, Table S2).  
 
Figure 2. Analysis of candidate cell surface gene expression levels by qRT-
PCR 
RNA isolated from the Ewing sarcoma cell lines A673, TC-32 and TTC466 and two 
MSC lines (5H and 4+v) was reverse transcribed into cDNA and analysed by qRT-
PCR. Expression levels were normalized against the house-keeping gene GAPDH 
and the Ewing sarcoma cell line A673 was used as a reference. Relative expression 
levels are given as 2-〉〉Ct with 〉Ct = CtLINGO1 – CtGAPDH, 〉〉Ct = 〉Ct Sample – 〉CtA673. 
The error bars represent the 95% confidence interval of the RQ (relative quantity) 
value.  
 
Figure 3. LINGO1 is differentially expressed in Ewing Sarcoma 
The association of LINGO1 mRNA and protein in Ewing sarcoma cells was 
confirmed by qRT-PCR and immunoblotting. 
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A. qRT-PCR analysis of eight Ewing sarcoma cell lines and three MSC lines. 
LINGO1 expression levels were normalized against the house-keeping gene GAPDH 
and the Ewing sarcoma cell line A673 was used as a reference. These are set at 1, 
i.e. A673 =100%. Relative expression levels are given as RQ (relative quantification) 
= 2-〉〉Ct with 〉Ct = CtLINGO1 – CtGAPDH, 〉〉Ct = 〉Ct Sample – 〉CtA673. The error bars 
represent the 95% confidence interval of the RQ value.  
B. Western blot analysis of LINGO1 protein. Lysates of Ewing sarcoma and MSC 
cells were fractionated by SDS-PAGE electrophoresis and analysed by Western 
blotting using the anti-LINGO1 antibody (Abcam). Expression of EWS-FLI1 was 
shown in A673, TC-32, CHP100, SKNMC, STAET1 (right hand panel) using an anti-
FLI1 antibody. Expression of either the alternative fusion protein EWS-ERG in TTC-
466, RM82 or the EWS-FEV fusion in STAET100 (left hand panel) was demonstrated 
using an anti-ERG antibody. Actin served as a protein loading control.  
C. LINGO1 is expressed in primary Ewing Sarcoma patient samples. Tissue 
microarrays containing cores from tumour biopsies were analyzed by 
immunohistochemistry using a mixture of two AlexaFluor 488-coupled (green) anti-
LINGO1 antibodies (Abcam and Millipore) and an Alexa-Fluor594-coupled (red) anti-
CD99 antibody (Thermo Scientific). Images were acquired by confocal laser 
scanning microscopy and analyzed using ImageJ software. LINGO1 expression 
levels were estimated based on staining intensities. The figure shows examples of 
weak (patient 778), medium (patient 786) and strong (patient 811) LINGO1 staining 
intensities (summarized data are given in SI Appendix, table S3). Paraffin embedded 
MSC tissue culture cells served as a negative control. Scale bars = 20µm. 
 
Figure 4: LINGO1 is expressed on the surface of Ewing Sarcoma cell lines 
LINGO1 surface expression in (A) EWS and (B) MSC cell lines was analyzed by 
FACS using the anti-LINGO1 antibody Li81 and a FITC-conjugated anti-human IgG 
secondary antibody. The x-axis shows log10 fluorescence intensities for LINGO1 
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antibody binding (blue) while the y-axis shows cell counts normalized to maximum of 
cells collected for each cell line. The cell staining with second antibody-only is shown 
in red.  
 
Figure 5: LINGO1 protein internalizes on Ewing Sarcoma cells when bound by 
bivalent antibody 
 LINGO1 is internalized and localizes to the early endosomes and lysosomes after 
binding anti-LINGO1 antibody. A673 Ewing sarcoma cells was treated with Alexa 
488-labeled (green) anti-LINGO1 Li81 antibody and incubated for 1.5 hours at 40C or 
370C. Cells were fixed and incubated with monoclonal rabbit antibody binding either 
the endosomal marker EEA1 (panel A) or the lysosomal marker LAMP1 (panel B) 
followed by incubation with Alexa 594-labeled (red) secondary anti-rabbit antibodies. 
Cell nuclei were stained using DAPI (blue).  
 
Figure 6. Effect of doxorubicin anti-LINGO1 antibody drug conjugate on viability of 
Ewing sarcoma cells 
A. The Ewing sarcoma cell line A673 expressing LINGO1 surface antigen was tested 
for sensitivity to doxorubicin. Cells were incubated in the absence or presence of 
increasing concentrations of doxorubicin and the cell viability was counted using the 
PrestoBlue assay at 48 hours. 
B. Li81 anti-LINGO1 antibody was converted to an ADC using next generation 
maleimide (34) and using in cell killing assays. A673 and MSC control cells were 
incubated for 48 or 72 hours in the presence of 100ug/ml Li81-ADC or Li81 alone. 
After the indicated incubation time, the cell viability was assayed using the 
PrestoBlue method. Values are normalized to cell number and viability of untreated 
cells. 
 
